{
  "id": "bc52e30e9ed2a5da",
  "title": "Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad",
  "description": "NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: \u2014 Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (\"BMW\"), one of 75+ brands within\u00a0the\u00a0Dynamic Brand Portfolio@IBN\u00a0(InvestorBrandNetwork)\r\n, a spe\u2026",
  "content": "NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (\"BMW\"), one of 75+ brands within\u00a0the\u00a0D\u2026 [+8255 chars]",
  "source": "GlobeNewswire",
  "source_url": "https://www.globenewswire.com/news-release/2025/12/05/3200703/0/en/Soligenix-Inc-NASDAQ-SNGX-Advancing-Rare-Disease-Therapies-Positioned-at-Pivotal-Crossroad.html",
  "published_at": "2025-12-05T13:30:00Z",
  "fetched_at": "2025-12-06T18:33:06.472112+00:00",
  "category": "politics_governance",
  "subcategory": null,
  "keywords": [
    "search:regulatory agency action"
  ],
  "location": null,
  "raw_data": {
    "source": {
      "id": null,
      "name": "GlobeNewswire"
    },
    "author": "Soligenix, Inc.",
    "title": "Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad",
    "description": "NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: \u2014 Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (\"BMW\"), one of 75+ brands within\u00a0the\u00a0Dynamic Brand Portfolio@IBN\u00a0(InvestorBrandNetwork)\r\n, a spe\u2026",
    "url": "https://www.globenewswire.com/news-release/2025/12/05/3200703/0/en/Soligenix-Inc-NASDAQ-SNGX-Advancing-Rare-Disease-Therapies-Positioned-at-Pivotal-Crossroad.html",
    "urlToImage": "https://ml.globenewswire.com/Resource/Download/d6acfc15-fbc6-4fcb-bad5-174367422824",
    "publishedAt": "2025-12-05T13:30:00Z",
    "content": "NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (\"BMW\"), one of 75+ brands within\u00a0the\u00a0D\u2026 [+8255 chars]"
  }
}